3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
8
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
15
Prostatic Neoplasms, Castration-Resistant
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Uveal Melanoma
1
Urothelial Cancer
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Sarcoma
1
Prostatic Diseases
1
Prostate Carcinoma Metastatic to the Bone
1
Prostate Adenocarcinoma
1
Penile Neoplasms
1
Ovarian Diseases
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Mesothelioma
1
Melanoma
1
Lung Neoplasms
1
Leukemia, Prolymphocytic, T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
pembrolizumab
18
Nivolumab
6
Radiotherapy
5
Paclitaxel
5
Trastuzumab
4
Specimen Handling
4
Ipilimumab
4
tisotumab vedotin
3
temsirolimus
3
olaparib
3
lenvatinib
3
X-Rays
3
Taxes
3
Surveys and Questionnaires
3
Early Intervention, Educational
3
Cyclophosphamide
3
Carboplatin
3
Biopsy
3
spartalizumab
2
sargramostim
2
rucaparib
2
palbociclib
2
fludarabine
2
epacadostat
2
enzalutamide
2
durvalumab
2
cabozantinib
2
atezolizumab
2
aflibercept
2
Vinorelbine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
niraparib
×
Genitourinary
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts